October 2017October 2017
New Product - Hexaxim
Hexaxim (DTPa-hepB-IPV-Hib vaccine) combines diphtheria toxoid, tetanus toxoid, acellular pertussis (toxoid and filamentous haemagglutinin), recombinant hepatitis B surface antigen, inactivated poliomyelitis virus and Haemophilus influenzae type b polysaccharide conjugated to tetanus protein. Hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b. Hexaxim should not be administered to anyone with a history of severe allergic reaction to any pertussis vaccine; encephalopathy of unknown aetiology within 7 days of administration of a previous dose of any vaccine containing pertussis antigens (whole cell or acellular pertussis vaccines); progressive neurological disorder, uncontrolled epilepsy or progressive encephalopathy until the treatment regimen has been established, the condition has stabilised and the benefit clearly outweighs the risk. Generally vaccination must be postponed in cases of moderate or severe febrile and/or acute disease. Hexaxim is supplied in a 0.5 mL single dose prefilled syringe (without attached needle and one or two separate needles) in a pack size of 1 or 10.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au